IMR Press / FBL / Volume 19 / Issue 2 / DOI: 10.2741/4213

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Review
CD157 at the intersection between leukocyte trafficking and epithelial ovarian cancer invasion
Show Less
1 Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126 Torino, Italy
Front. Biosci. (Landmark Ed) 2014, 19(2), 366–378; https://doi.org/10.2741/4213
Published: 1 January 2014
Abstract

CD157 is a member of the ADP-ribosyl cyclase gene family that is involved in the metabolism of NAD. CD157 behaves both as an ectoenzyme and as a receptor. Though CD157 is anchored to the membrane by a glycosylphosphatidylinositol moiety, which makes it unsuitable to transduce signals on its own, it exploits its localization in selected membrane microdomains and its proclivity to interact with integrins to accomplish receptor functions. Initially characterized as a stromal and myeloid antigen involved in the control of leukocyte adhesion, migration and diapedesis, CD157 was subsequently found to have a far wider distribution. In particular, CD157 was found to be expressed by epithelial ovarian cancer cells where it is involved in interactions among tumor cells, extracellular matrix proteins and mesothelium. The overall picture inferred from experimental and clinical observations is that CD157 is a critical player both in leukocyte trafficking and in ovarian cancer invasion and metastasis formation. In this review, we will discuss the biological mechanisms underpinning the role of CD157 in the control of leukocyte migration and ovarian cancer dissemination.

Keywords
Leukocyte Trafficking
CD157
BST-1
Signal Transduction
Ovarian Cancer
Tumor Dissemination
Epithelial-Mesenchymal Transition
Review
Share
Back to top